Big Pharma is pouring billions into a new class of ‘protein degrader’ drugs that target previously undruggable proteins in diseased cells. These medications, which include molecules like ARV-471 and KT-474, work by tagging harmful proteins for destruction by the cell’s natural recycling system. Early clinical trials have shown promising results in treating cancers and autoimmune diseases, areas where traditional small-molecule drugs have struggled.
Companies like Pfizer, Bristol Myers Squibb, and Novartis are leading the charge, with partnerships and acquisitions totaling over $5 billion in recent years. The technology represents a shift from simply blocking proteins to eliminating them entirely, offering a new frontier in therapeutic development. Analysts predict the market could reach $20 billion by 2030, driven by the potential to treat a wide range of previously untreatable conditions.
উৎস: Wall Street Journal US Business · সারাংশ: HeadlinesBriefing